ITALIAN HI-TECH INDUSTRY: THE CASE OF LIFE SCIENCES
|
|
- Cornelius Harmon
- 6 years ago
- Views:
Transcription
1 ITALIAN HI-TECH INDUSTRY: THE CASE OF LIFE SCIENCES Part Two Executive summary National Interest January 2015 Study conducted by the IMT Institute for Advanced Studies Lucca, the Fondazione CERM, AIFA, and the Centro Studi Farmindustria for Aspen Institute Italia Aspen Institute Italia
2 Executive Summary This study provides a snapshot of the state of health of the life sciences sector in Italy, as well as a comparison of the sector s performance against the main economic and scientific indicators, both before and after the crisis of 2008, with that of the major developed and emerging countries. The picture that emerges points to certain strengths and the resilience of the industry, which remains one of the leaders in Europe for production and export, as well as highlighting continuing difficulties in retaining Italian talent and attracting skilled human capital from abroad. The availability of skilled human capital particularly science graduates at a cost that remains relatively low, together with the high productivity discernible from the performance figures for firms in the sector, constitute competitive advantages that have unquestionably enabled Italy to consolidate existing investments in recent times and to attract foreign capital, thereby affording the country real prospects of assuming a key role as a production base for the European market. Italy s research system boasts levels of scientific output in the pharmaceutical, biomedical and biological fields that are comparable with those of the leading countries in the world, although it also suffers from below-average patent production rates. A growing proportion of inventions by Italian researchers are being patented by foreign multinationals. An examination of industrial trends over the course of the deep and protracted crisis that has hit Italian manufacturing highlights the importance of the life sciences sector. On a global scale, the sector s resilience is attributable to stable demand, the greater average size of its firms, their more pronounced international market presence, and their ability to innovate, with the crisis period witnessing a rise in the number of innovative new drugs launched internationally. On a national scale, what stands out is an ability to increase exports by tapping into growing shares of world demand. This is a key factor for heavily-internationalized sectors in which the localization choices of firms determine performance in terms of production and research, and an aspect that makes the competitiveness of firms, the national innovation system and the country s economy in general a pressing issue. The crisis has contributed to an albeit slight exacerbation of the relative lag with which innovations in the bio-pharmaceutical field may be accessed in Italy, due mainly to fragmentation of the regulatory framework between the state and regions. As part of the study, movements in the localization of patents, publications, inventors and businesses were mapped to geographic precision using mapping tools offered by Google and Yahoo!, enabling the evolution of research clusters and industrial districts to be traced over time. This analysis reveals a tendency towards the progressive marginalization, in Italy, of local scientific and technological research systems a trend which seems attributable to a high level of fragmentation in the national research system, in addition to difficulties in making the public and private research spheres interact with each other, and the growing attractiveness of the foremost global and European research centers Italy is facing new challenges stemming from the intensive processes of integration and convergence that are characterizing advancement in the frontiers of scientific and technological research in a number of areas, including: a) new materials for the reconstruction and regeneration of tissue, for diagnostics and for minimally invasive prostheses; b) simulation and analytical models as the basis for new approaches to tackling the neurological mechanisms characteristic of neurodegenerative disorders, such as Alzheimer s and Parkinson s; c) the development of new Aspen Institute Italia National Interest Italian hi-tech industry: the case of life sciences 2
3 techniques and materials for cellular regeneration; and d) the development and use of new imaging techniques. In this convergence of scientific and technological trajectories formerly considered far-removed from each other, possibilities for successful business ventures arise at the interface of fields such as biomedicine, pharmaceutics, biotechnology, new materials, and information technology. Italian start-ups may have opportunities for breaking into these areas, with excellent results even on a small scale. In contrast, the public research system is laboring under greater difficulties, with a seeming inability to implement innovative organizational models that would facilitate the establishment of multidisciplinary laboratories and would bring educational syllabuses up-to-speed to take account of and, where possible, enable a leading role to be played in the expansion of the frontiers of scientific and technological research. Notable at a global level has been the inexorable rise of the Boston, Bay Area and San Diego clusters, where all the research activities of multinational pharmaceutical companies and the major university and hospital research centers are concentrated. In terms of the sector s growth prospects and industrial policy, certain areas for action emerged which could enable the potential of life sciences to be fully tapped, including with a view to increasing the competitiveness of Italy both in the research sphere and in hi-tech and scientific research-based sectors. The sector is already, for that matter, kick-starting a recovery trajectory, in some ways anticipating a trend that will hopefully encompass the entire Italian economy. The research world of the past has undergone significant changes. Biopharmaceutical research today is characterized by a strong level of competitiveness, and it is no longer just the size of the individual firm that matters, but also the quality and level of specialization of the sector and of the relevant institutional framework. In this new competitive scenario, the current patent system is totally obsolete: there is a need to move away from an approach that focuses primarily on patent protection towards one based on protection of shared innovation. One important field with scope for further development is that of hospital research, especially in the area of clinical studies. In this context, specialized operators such as Contract Research Organizations (CROs), together with a growing number of start-ups, are stepping up their activities in Italy, in the process enhancing the skills of leading hospital facilities in the conduct of clinical trials. Against this backdrop, which confirms the attractiveness of Italian facilities, it is important to ensure that the country is able to play a growing role in Europe in the conduct also of Phase I clinical trials. A second priority area arises from the need to strengthen the main Italian innovation clusters in Rome and Milan, by increasing their centrality to the national research system. Greater consolidation into poles of research is a necessary precondition for attracting and retaining investment and skilled human capital, thereby regaining a role in global division-of-innovativelabor networks. Crucial in this regard will be the ability to provide a strong boost to the internationalization of the recruitment of young researchers and students, as well as to the innovation of research and teaching organizational models, which are still exceedingly polarized along traditional educational lines according to relatively self-contained disciplinary strands. There is a need to increase the capacity to conduct applied research by facilitating the patenting of inventions developed in the public sector, including through the strengthening of collaboration with the private sector. The interviews conducted during the study showed a growing propensity on the part of Italian firms in the biotech, pharmaceutical and biomedical sectors to collaborate with university research centers in Italy and abroad. Many of these collaborative ventures are accomplished through confidentiality undertakings, material transfer agreements or the forging of Aspen Institute Italia National Interest Italian hi-tech industry: the case of life sciences 3
4 partnerships on behalf of third parties. The development of intellectual property is left almost entirely to private-sector operators, while the patent committees of Italian universities emerge as poorly equipped to fulfill their role, often lacking the necessary expertise. The intellectual property stemming from the outcomes of Italian research is frequently capitalized on by third parties, often outside the country. Lately, some Italian universities have been developing an entrepreneurial vision for the management of intellectual property that facilitates collaboration, although sometimes this can create competitive tensions with firms over licenses and royalties. On another front, it also comes down to promoting conditions that facilitate access to risk capital and credit for hi-tech startups. Notwithstanding the significant progress made in this regard, the international crisis has produced a scenario characterized by asymmetries between national innovation systems which must be taken into account. Finally, in order to increase the country s competitiveness, it is essential to strengthen national regulatory bodies, equipping them with adequate resources and personnel to streamline authorization processes, thereby improving procedures and avoiding duplication and the fragmentation of powers across various levels of jurisdiction. Some of the main empirical findings of the study can be summarized as follows: * In Italy, the pharmaceutical and medtech industries have increased their contribution to the economy in terms of value-added (up from 5% to 6% of manufacturing industry from 2008 to 2013), and even more so in terms of exports (up from 5% to 7%). * The life sciences sector is characterized by a significantly higher-than-average level of productivity, while the pharmaceutical industry is the leading manufacturing sector. Investments are also above average levels, contributing to the productivity result as well as to an excellent quality-to-cost ratio for human resources. * European Commission data puts life sciences among the top rankings for long-term industrial growth. The European Union, as a whole, has the world s largest manufacturing output, while Germany, Italy, the United Kingdom and France together persistently account for more than half of European value-added. * For every euro spent in the pharmaceutical sector in Italy, the impact on the economy of the country is almost double. In particular, for every employee in the pharmaceutical industry, at least one other person finds employment in allied industries. The multiplier effect of the Italian pharmaceutical sector is higher than the average for European countries and than for the United States, confirming the country has a stronger manufacturing bent than its other major international competitors. * In terms of research, the pharmaceutical and medtech industries have greater links with external centers of excellence than other sectors, as shown by the degree of openness of firms to extramural R&D, which is 55% higher than the average for manufacturing. In particular, the pharmaceutical sector is the leading industry in this regard, recording a 25% growth in spend on outsourced R&D between 2008 and 2012, in line with trends seen in the major European countries. * In Italy, life sciences is the sector which attracts the most foreign investment. Despite the sector being increasingly integrated into the global economy, much of its value-added is still created and retained within national borders. In Germany, the sector accounts for 86% of Aspen Institute Italia National Interest Italian hi-tech industry: the case of life sciences 4
5 domestic value-added, while in Italy it is around 72%. In the medium to long term, the role of the BRIC countries and the rest of the world as a source of intermediate inputs will increase. Italy remains one of the leading pharmaceuticals producers in Europe, with productivity growth in line with that of its major European partners. * As regards the clinical testing of drugs in Italy, figures in the latest report from AIFA show a fall in the total number of trials, due to a reduction in clinical studies conducted by public agencies. However, an increase was noted in Phase I trials, which for the first time topped 10%, resulting in an overall increase in so-called early-phase testing, which amounted to 45% of the total number of trials given the go-ahead. Italy s share of clinical trials in the European Union was 17.2%, in line with previous years. * The clinical phase is also pivotal for medtech manufacturers, over half of whom invest in preor post-marketing studies. Clinical studies are becoming increasingly important, rising from 21% of total R&D spend in 2010 to 34% in 2013, posting an increase in value of over 30%. * In the course of the study, the names of inventors were drawn from 2.4 million patents registered with the European Patent Office. Observing changes of address for inventors between two consecutive patents, 20,000 cases were identified of inventors in the life sciences field who had moved. The analysis reveals that the countries at the center of the mobility network in Europe are Switzerland and Germany, with the former showing a net influx of talent from abroad. Italy, in contrast, recorded a net exodus. * In Italy, there is a higher percentage of inventor rather than institutional patent holders. This differential has been increasing over time, due in the main to the progressive reduction in the proportion of patents awarded to Italian firms. The number of inventions of Italian researchers affiliated with foreign multinationals is on the rise. * The scientific and patenting output of Italy in the field of life sciences was analyzed, with the data for scientific publications sourced from SCImago and Pubmed, while on the patenting front, triadic patents (filed in Europe, the United States and Japan) were considered as a gauge of inventions of global significance. Among the more developed countries, Italy has a high scientific publication output which is showing modest growth, especially in the pharmaceutical field. Also observable is the rapid rise of China into the ranks of the countries with the highest number of publications. Italy is among the countries most specialized in biomedical and pharmaceutical research, although its rating on the relative specialization index (proportion of publications in the field of life sciences to total national scientific publication output) is in decline, especially in the fields of biochemistry and biotechnology. * In terms of the total number of citations garnered by scientific works, Italy s relative position has remained essentially unchanged. In the biomedical field, the value of scientific publications, measured by the number of citations, is high and growing. However, the degree of internationalization of Italian research in the field of life sciences is still limited. In particular, it is notable that there has been a fairly small increase in the number of international publications in the pharmaceutical and biomedical fields. Aspen Institute Italia National Interest Italian hi-tech industry: the case of life sciences 5
6 * When patent production is considered, Italy s position emerges as notably weaker. The country s ranking has worsened in all areas of research during the crisis, and, in particular, in the more patent-intensive fields (biotechnology and pharmaceuticals). There continues to be difficulty in turning the potential of basic research into innovation (patents-to-publications ratio) a difficulty which has grown progressively worse over the course of the crisis, with a negative impact, in the medium to long term, on the ability to generate industrial value. * The main Italian research clusters in the field of life sciences occupy relatively low positions in the world ranking. The top three clusters for total Impact Factor of scientific publications (source: Pubmed) are Rome (in 258 th place), Pisa (in 344 th place) and Milan (in 347 th place). If only the number of publications is considered, then Rome and Milan are placed 122 nd and 125 th respectively. The average level of research produced in the main Italian clusters reflects the difficulty of attracting talent from abroad and retaining the best Italian researchers. * Overall, Italy s research clusters still lag too far behind in the global division-of-innovativelabor network. An analysis of the content of scientific publications reveals that Italian research centers do not always work on issues that are at the cutting-edge of biomedical research, from which fact stems the reduced average impact of Italian scientific output. Aspen Institute Italia National Interest Italian hi-tech industry: the case of life sciences 6
Policies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationL A B O R M A R K E T B R I E F I N G S S E R I E S
L A B O R M A R K E T B R I E F I N G S S E R I E S LABOR MARKET INFORMATION FOR RESEARCHERS THE LIFE SCIENCE AND PHARMACEUTICALS SECTOR IN EUROPE L I F E S C I E N C E A N D P H A R M A C E U T I C A
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More information6. Vision 3: Leading the Japanese economy forward as a high value-added industry"
6. Vision 3: Leading the Japanese economy forward as a high value-added industry" Strategic points for realizing the vision Streamlining and rationalization R&D to create innovative drugs Proactively introducing
More informationThe Innovation Union Scoreboard: Monitoring the innovation performance of the 27 EU Member States
MEMO/12/74 Brussels, 7 February 2012 The Innovation Union Scoreboard: Monitoring the innovation performance of the 27 EU Member States This MEMO provides an overview of the research and innovation performance
More informationFacts&figures of the Pharmaceutical industry in Italy. July 2018
Facts&figures of the Pharmaceutical industry in Italy July 2018 Key figures of the Pharma sector in Italy Pharma industry in Italy by nationality of ownership (% on total) 40% Italian-owned companies 200
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationnuclear A new deal for It s time to develop a fresh vision that will realise the potential of the UK s civil nuclear industry
A new deal for nuclear Latest revision of this document: https://library.prospect.org.uk/id/2017/00997 This revision: https://library.prospect.org.uk/id/2017/00997/2017-06-30 It s time to develop a fresh
More informationEnhancing management quality:
Improving the quality of management in UK firms could lead to significant gains in national productivity. Rebecca Homkes outlines the latest findings of CEP s research programme on the impact of management
More informationThe fisheries sector in Italy
The fisheries sector in Italy Check-up 2008 Executive Summary The Check-up on the Italian fisheries sector provides an analysis of fishing, aquaculture and the fish and seafood processing industry, using
More informationBackground document Region FVG. Introduction. Socio-economic profile. The definition of Friuli Venezia Giulia RIS3
Background document Region FVG The Smart Specialisation Strategy of Region Friuli Venezia Giulia Introduction Friuli Venezia Giulia is one of the five autonomous regions with a special statute and it is
More informationIstanbul Industry Outlook
Istanbul Industry Outlook Istanbul Industry Outlook Survey 18th April 2018 300+ Istanbul manufacturers Representative data from Purchasing Managers Index (PMI ) survey panels Unique perspective Business
More informationDevelop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers:
MEDICON VALLEY / 2011 03 Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers: > A pool of highly qualified life-science university graduates and
More informationThe Future of Industry in Europe
The Future of Industry in Europe Michele Alessandrini and Pietro Celotti (t33, Ancona, Italy) CoR Workshop The Future of Industry in Europe Challenges and Instruments for Local and Regional Authorities
More informationIN BRIEF Uncertainties such as Brexit and weak global demand loom large. But German manufacturers propensity to innovate leave it better positioned th
GERMANY TRADE REPORT IN BRIEF Uncertainties such as Brexit and weak global demand loom large. But German manufacturers propensity to innovate leave it better positioned than other EU economies. Germany
More informationHIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN POINTS
HIGH-TECH INDUSTRIES BIOTECH IN FRANCE KEY INFO IN 10 POINTS 1 67 BILLION IN REVENUES The biotech-medtech industry accounted for around 330,000 direct and indirect jobs and 67 billion in sales in 2016
More informationSkilled labour Published on Innovation Policy Platform (
Skilled labour Access to skilled labour is key for innovation in firms: skilled labour can contribute to innovation and growth by generating new knowledge, developing incremental innovations, supporting
More informationNational Competitiveness Council s Productivity Statement Productivity Statement 2018
National Competitiveness Council s Productivity Statement 2018 Productivity Statement 2018 1 November 2018 Summary Productivity growth is a key determinant of national competitiveness, enabling firms to
More informationVERMONT. Bioscience Performance Metrics. Vermont Page 1
VERMONT Vermont has developed a specialized employment concentration in medical devices and equipment (location quotient of 1.43). The State s $97 million in academic bioscience research and development
More informationRoad map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1
Road map for the PMDA International Vision April 2013 Pharmaceuticals and Medical Devices Agency, Japan 1 1. Introduction The Pharmaceuticals and Medical Devices Agency (PMDA), a Japanese Incorporated
More informationCONNECTICUT. Bioscience Performance Metrics. Connecticut Page 1
CONNECTICUT Connecticut has a specialized and diverse concentration of employment in the overall bioscience industry and in two of its subsectors: drugs and pharmaceuticals (location quotient of 2.01)
More informationLA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES
LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES Francesca Pasinelli Direttore Generale 3 Congresso Nazionale SIFaCT Roma, 9 ottobre 2015 About Telethon Fondazione Telethon is
More informationPENNSYLVANIA. Bioscience Performance Metrics. Pennsylvania Page 1
PENNSYLVANIA Pennsylvania has a leading and specialized bioscience industry. Among the four major subsectors, the State has a specialized employment concentration in two drugs and pharmaceuticals (location
More informationUniversità Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
More informationBIOTECH IN FRANCE. key info in. points
BIOTECH IN FRANCE 10 key info in points 1 2 3 INSERM: EUROPE S #1 ACADEMIC BIOTECH RESEARCH INSTITUTE INSERM spearheads healthcare and medical research in France, filing more biotech patents with the European
More informationIOWA. Bioscience Performance Metrics. Iowa Page 1
IOWA Iowa has a highly concentrated and rapidly growing bioscience industry. Iowa has nearly 7 percent of national employment, faster growth than the national average, and a highly specialized concentration
More informationSUPPLEMENT TO THE GOVERNMENT S BUDGETARY POLICY ACTION. Support for the Biotechnology Sector
SUPPLEMENT TO THE GOVERNMENT S BUDGETARY POLICY 2002-2003 ACTION Support for the Biotechnology Sector Support for the Biotechnology Sector ISBN 2-550-38981-6 Legal deposit Bibliothèque nationale du Québec,
More informationThe Globalization of Biotechnology. Alicia Löffler Northwestern University
The Globalization of Biotechnology Alicia Löffler Northwestern University Let me start with the conclusion The US has a historic opportunity to establish a long-term position as a global hub in biotechnology.
More informationMARKETS & CUSTOMERS. Progressing globalization. Evolving markets
Peptides are used worldwide in medical research. They contribute immensely to the understanding of diseases and have proven to be effective in medicinal products. Today, peptides can be produced at low
More informationInnovation: A Sectoral Outlook
Towards a Québec Innovation Policy Innovation: A Sectoral Outlook (Aerospace, Pharmaceuticals, Forest Products) Advisory report of the Conseil de la science et de la technologie Summary Innovation in Québec
More informationSpotlight on: Staffing and retention. Pharma, biotech and medical devices
Spotlight on: Staffing and retention Pharma, biotech and medical devices A US perspective 2013 Expansion, mergers, acquisitions and competition have impacted on salary and benefit expectations, and the
More informationParioforma. Pharmaceutics Landscape - summary. (formerly RM Consulting) April 2005
Parioforma (formerly RM Consulting) Pharmaceutics Landscape - summary April 2005 Parioforma Ltd 55 Princes Gate Exhibition Road South Kensington London SW7 2PN United Kingdom Tel: +44 (0) 207-225-3538
More informationBiopeople at a Glance
Biopeople at a Glance Future Directions in Regulatory Science Copenhagen 21 April 2016 Per Spindler, Director www.biopeople.dk Welcome to Biopeople Biopeople, Faculty of Health and Medical Sciences, University
More informationSTATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY
STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY State of the Asia-Pacific Pharmaceutical Industry The pharmaceutical industry in the Asia-Pacific region has recently been besieged
More informationHannover, your first foothold for business expansion into Europe
Hannover, your first foothold for business expansion into Europe Hannover Clinical Trial Center & hannoverimpuls Support for entering the health care market 1 The Hannover Region features all important
More informationMARYLAND. Bioscience Performance Metrics. Maryland Page 1
MARYLAND Maryland is home to a specialized and rapidly growing bioscience industry. The State s largest bioscience subsector, research, testing and medical laboratories is also its most specialized in
More informationKauffman Dissertation Executive Summary
Kauffman Dissertation Executive Summary Part of the Ewing Marion Kauffman Foundation s Emerging Scholars initiative, the Kauffman Dissertation Fellowship Program recognizes exceptional doctoral students
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationBio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of
More informationSAMPLE. South Korea MRI Systems Market Outlook to Reference Code: GDMECC0287DB. Publication Date: March 2014
South Korea MRI Systems Market Outlook to 2020 Reference Code: GDMECC0287DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationCALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY
CALIFORNIA S BIOTECHNOLOGY WORKFORCE TRAINING NEEDS FOR THE 21 st CENTURY Executive Summary Prepared for Applied Biological Technologies Initiative Economic and Workforce Development Program California
More information2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award 2018 2018 NORTH AMERICAN REAL-WORLD EVIDENCE ENTERPRISE SOLUTIONS MARKET LEADERSHIP AWARD Contents Background and Company
More informationSOFIDEL GROUP: 50 YEARS OF GROWTH INTO THE FUTURE
Press release SOFIDEL GROUP: 50 YEARS OF GROWTH INTO THE FUTURE From a company from the province of Lucca to a multinational - particularly well-known for the Regina brand - which is currently present
More informationThe Riksbank s Business Survey RECOVERY CONTINUES BUT UNCERTAINTY RETURNS
The Riksbank s Business Survey RECOVERY CONTINUES BUT UNCERTAINTY RETURNS SEPTEMBER 214 The Riksbank s Business Survey in September 214 Economic activity is continuing to slowly improve according to the
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION STAFF WORKING DOCUMENT. Accompanying document to the
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 15.5.2007 SEC(2007) 569 COMMISSION STAFF WORKING DOCUMENT Accompanying document to the Proposal for the Council Regulation concerning the setting up the
More informationIntellectual property: The driving force for growth and funding
Judith E. Schneider is Chairman and Chief Executive Officer of The BPI Group Limited, a leading professional services firm providing strategic advisory and business plan development services to emerging
More informationCurrent Topics of Pharmaceutical Regulatory Affairs in Japan
Pharmaceuticals and Medical Devices Agency Current Topics of Pharmaceutical Regulatory Affairs in Japan Takeyuki SATO Associate Director (International and Product Evaluation Affairs), Centre for Product
More informationSwiss Software Industry Survey 2018 Current State, Emerging Trends & Long-term Developments in the Swiss Software Industry
THOMAS HURNI, THOMAS L. HUBER & JENS DIBBERN INSTITUTE OF INFORMATION SYSTEMS Swiss Software Industry Survey 2018 Current State, Emerging Trends & Long-term Developments in the Swiss Software Industry
More informationContents. Barometer of business climate in Spain, Results 2016 Contents 2
Results 2016 Contents 1. Presentation 3 2. Executive summary 5 3. Background 7 4. General results 9 4.1. General assessment 10 4.2. Main strengths and weaknesses 11 4.3. Comparison 2015-2016 12 4.4. Main
More informationSUBMISSION FROM NORTH AYRSHIRE COUNCIL
1. Introduction SUBMISSION FROM NORTH AYRSHIRE COUNCIL The purpose of this report is to assist and inform the Committee s inquiry into the Living Wage, by setting out the background and the context of
More informationSummary of Evidence Session Management 1 Hal Varian, John Van Reenen, and Ian Davies, 28 th of May 2012
Summary of Evidence Session Management 1 Hal Varian, John Van Reenen, and Ian Davies, 28 th of May 2012 The LSE Growth Commission has been organising a series of evidence sessions with leading thinkers
More informationTechnology Transfer, Academic and Industry Cooperations
Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and
More informationThe Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports
The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationExporting, Importing and Countertrade
Lecture 9 Exporting, Importing and Countertrade Introduction Large and small firms export Exporting is on the rise thanks to the decline in trade barriers under the WTO and regional economic agreements
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationAMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN
News Release AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN TOKYO (Dec. 20, 2016) Amgen Astellas BioPharma K.K. (Headquarters,
More informationSWOT Analysis Strengths, Weaknesses, Opportunites and Threats (SWOT). SWOT strengths, weaknesses, opportunities, and threats.
SWOT Analysis Strengths, Weaknesses, Opportunites and Threats (SWOT). SWOT analysis is a tool for auditing an organization and its environment. It is the first stage of planning and helps marketers to
More informationPromoting the Biotechnology Industry in Germany
Positions Promoting the Biotechnology Industry in Germany Germany s biotechnology industry ranks among the most sustainable and forward looking of today s cutting-edge technologies. Biotechnology is about
More informationThird Pillar: Knowledge, Innovation and Scientific Research
3 rd Pillar: Knowledge, Innovation & Scientific Third Pillar: Knowledge, Innovation and Scientific Overview of Current Situation The concept of knowledge,, and scientific research expands to include the
More informationBarometer of the business
Barometer of the business Results 2017 Contents 1. Presentation 3 2. Executive summary 5 3. Background 7 4. General results 9 4.1. General assessment 10 4.2. Main strengths and weaknesses 11 4.3. Comparison
More informationOliver Wyman study Automotive Suppliers in China China is key to the success of European automotive suppliers
M A N A G E M E N T S U M M A R Y Oliver Wyman study Automotive Suppliers in China China is key to the success of European automotive suppliers European automotive suppliers need to maintain a strategic
More informationThe multinational enterprise
CHAPTER 2 The multinational enterprise Chapter objectives 1. Describe the characteristics of multinational enterprises. 2. Explain the internationalization process. 3. Explain why firms become multinational
More informationdownload instant at
CHAPTER 2 The multinational enterprise Chapter objectives 1. Describe the characteristics of multinational enterprises. 2. Explain the internationalization process. 3. Explain why firms become multinational
More informationEuropean Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU
European Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU Ravinder Chahil Director of Intellectual Property Polpharma Group SA 8 March 2016 Content Commission
More informationRHODE ISLAND. Bioscience Performance Metrics. Rhode Island Page 1
RHODE ISLAND Rhode Island has a specialized employment concentration in two growing bioscience industry subsectors drugs and pharmaceuticals (location quotient of 1.) and medical devices and equipment
More informationClinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013
Clinical Trials: Facts and Trends Dr Nik Nikitin Founder/Director, Russlan Clinical What is a clinical trial? A clinical trial is a research study in human volunteers to answer specific health questions
More informationSwiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou
Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou 1 Overview 1. Overview European Medtech Venture Valuation: Independent assessment and valuation of technology driven companies
More informationWednesday October 14, Invitation only. For more information, please visit
Wednesday October 14, 2015 Startup Acceleration Training (8:00-15:00) Sponsored by: 08:00-15:00 Invitation only. For more information, please visit http://goo.gl/forms/fpm0vdyciz. Biocluster Workshop -
More informationJournal of Chemical and Pharmaceutical Research, 2014, 6(7): Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(7):1291-1295 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 A study of American nanotechnology development
More informationBasic Information. I.1 If your company performs biotechnology research and development, uses a. The Categories of Biotechnology Applications.
APPENDIX 2 SURVEY QUESTIONNAIRE Part I. Basic Information I.1 If your company performs biotechnology research and development, uses a biotechnology process in manufacturing, or produces research tools,
More informationThe European Medical Technology Industry. in figures / 2018
The European Medical Technology Industry in figures / 2018 Table of contents What is Medical Technology? 4 Innovation 10 Employment 14 Companies 18 Expenditure on Medical Technology 20 MedTech Market in
More informationSurvey on ICT-enabled Services Exports
Survey on ICT-enabled Services Exports Thierry COULET Consultant UNCTAD Training for Pilot Survey 13-14 July 2017 Ministry of Commerce and Industry, Kolkata, India 1 OUTLINE OF PRESENTATION Background
More informationPolicy Note August 2015
Unit Labour Costs, Wages and Productivity in Malta: A Sectoral and Cross-Country Analysis Brian Micallef 1 Policy Note August 2015 1 The author is a Senior Research Economist in the Bank s Modelling and
More informationInnovative Medicines Initiative (IMI) and other Public Private Partnerships: Educational Ambitions
Innovative Medicines Initiative (IMI) and other Public Private Partnerships: Educational Ambitions Oslo EAFP 19 June 2009 1200 km 2 2 Billion EURO 1 Billion Euro 1 Billion Euro Public Private Partnership
More informationIntroduction: Commercial Activity
Chapter 3 Introduction: Commercial Activity Ifentrepreneurs and arbitrageurs were our heroes of the 80s, we hope scientists and engineers will be the stars of the 90s. Mary Ann Liebert Genetic Engineering
More information2016 Global Manufacturing Competitiveness Index Report highlights
2016 Global Manufacturing Competitiveness Index Report highlights Years of successful collaboration exploring manufacturing competitiveness In collaboration with leading organizations, Deloitte has explored
More informationFinancial Information
Financial Information of 4.9 billion in Q1 2011, Continued strong organic at +12% Industry continued on a very solid momentum IT and Buildings expanded at double-digit thanks to solutions Power also solid,
More informationList of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1
Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted
More informationThe Bio-Health Industry in Denmark
The Bio-Health Industry in Denmark A strategy and 10 recommendations from the Vision Round Table for Biotechnology, Health Care and Industrial Development Preface The bio-health industry is one of the
More informationAustralia: A Dynamic Environment for Conducting Clinical Trials
Australia: A Dynamic Environment for Conducting Clinical Trials MTPConnect s goal is to accelerate the growth of Australia s MTP sector Industry Associations Governments Universities Researchers Investors
More informationInvesting in people TALENT ACQUISITION TRAINING AND DEVELOPMENT
Investing in people For the Prysmian Group, intellectual capital and talent are strategic assets for the achievement of our profitability and value creation objectives and, as such, must be supported by
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationMeasuring innovation West Africa Regional Science, Technology and Innovation Policy Reviews and Statistics Workshop Bamako, Mali May 2010
Measuring innovation West Africa Regional Science, Technology and Innovation Policy Reviews and Statistics Workshop Bamako, Mali 10-13 May 2010 Measuring Innovation Oslo Manual - 2005: (Guidelines for
More informationAnnual General Meeting Roche Holding Ltd
r Annual General Meeting Roche Holding Ltd 5 March 2019 Address by Christoph Franz Chairman of the Board of Directors (Check against delivery) Address by Christoph Franz page 2/12 Shareholders, ladies
More informationSector: Agriculture. Keywords: Bulgaria, Sofia, Food Products and Agriculture, Agricultural sector. Abstract:
MINISTRY OF FOREIGN AFFAIRS OF DENMARK THE TRADE COUNCIL AGRICULTURE SECTOR BULGARIA Sector: Agriculture Prepared by the Danish embassy in Sofia May 2012 Keywords: Bulgaria, Sofia, Food Products and Agriculture,
More informationThe chemical industry in Italy: situation and outlook
The chemical industry in Italy: situation and outlook August 2017 For information: Centro Studi Federchimica Phone 02/34565.337 - Mail aei@federchimica.it A good start in 2017 for chemical industry in
More informationIndustrial Renaissance. The Role of Europe, the Contribution of Italy. Speech of President Fabio Storchi
Industrial Renaissance The Role of Europe, the Contribution of Italy Speech of President Fabio Storchi 1. Introduction Since the beginning of the crisis seven years ago, in Europe, particularly in the
More informationPOSITION OF THE CZECH REPUBLIC IN COMPETITIVENESS RANKINGS
POSITION OF THE CZECH REPUBLIC IN COMPETITIVENESS RANKINGS Marta Nečadová Hana Scholleová Abstract Competitiveness of the Czech economy as a whole follows from enterprises ability to indentify, apply and
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationSpain Knee Replacement Procedures Outlook to 2020
Spain Knee Replacement Procedures Outlook to 2020 Reference Code: GDMECC0052PDB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationBibliometric analysis of GRDI-funded researchers international scientific collaboration
Bibliometric analysis of GRDI-funded researchers international scientific collaboration Introduction/Objectives 1- Overview of GRDI-funded scientists international scientific collaboration: Trends in their
More informationLeading domestic players in India s pharmaceutical market in 2015
THE INDIAN PHARMACEUTICAL MARKET LEADING DOMESTIC COMPANIES 2015 Leading domestic players in India s pharmaceutical market in 2015 1 Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods
More informationSAMPLE. North America Trauma Fixation Procedures Outlook to 2020
North America Trauma Fixation Procedures Outlook to 2020 Reference Code: GDMECR0008PDB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationreport on the Italian automotive sector Camera di commercio di Torino
Observatory 2012 report on the Italian automotive sector Torino Chamber of Commerce Industry Crafts and Agriculture in collaboration with Chieti Chamber of commerce Industry Crafts and Agriculture and
More informationTerritory Account Manager (MD, NC or TX based)
Territory Account Manager (MD, NC or TX based) Looking for bilingual Chinese-English young professionals with passion in selling genomics services. The Territory Account Manager's role is to ensure achievement
More informationCapacity-building of Scientific Personnel India
10 Capacity-building of Scientific Personnel India GENERAL INFORMATION Implementing Institution: International Centre for Genetic Engineering and Biotechnology (ICGEB) Head: Professor F. E. Baralle, Director-General,
More information